Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.
1. A method of treating heart failure associated with preserved ejection fraction (HFpEF) in a subject, the method comprising providing to a subject having HFpEF a compound represented by formula (X):
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the HFpEF is associated with a condition selected from the group consisting of hypertension, obesity, and diabetes.
3. The method of claim 1 , wherein the compound is provided in a pharmaceutical composition.
4. The method of claim 3 , wherein the pharmaceutical composition is provided orally.
5. The method of claim 4 , wherein the composition comprises a format selected from the group consisting of a tablet, troche, lozenge, aqueous suspension, oily suspension, emulsion, hard capsule, soft capsule, and syrup.
6. The method of claim 3 , wherein the pharmaceutical composition comprises a mixture of the compound and an erodible polymer that promotes swelling of the mixture in an aqueous environment.
7. The method of claim 6 , wherein the erodible polymer is hydroxypropyl methylcellulose (HPMC).
8. The method of claim 7 , wherein the mixture comprises the compound and HPMC in a ratio of from about 1:10 to about 10:1.
9. The method of claim 3 , wherein the pharmaceutical composition is a unit dosage comprising from about 10 mg to about 500 mg of the compound.
10. The method of claim 3 , wherein the pharmaceutical composition comprises a crystal comprising a Form A polymorph of the compound.
11. The method of claim 10 , wherein the crystal comprises a hydrochloride salt of the compound.
12. A method of treating heart failure associated with preserved ejection fraction (HFpEF) in a subject, the method comprising providing to a subject having HFpEF a compound represented by formula (IX):
or a pharmaceutically acceptable salt thereof.
13. The method of claim 12 , wherein the HFpEF is associated with a condition selected from the group consisting of hypertension, obesity, and diabetes.
14. The method of claim 12 , wherein the compound is provided in a pharmaceutical composition.
15. The method of claim 14 , wherein the pharmaceutical composition is provided orally.
16. The method of claim 15 , wherein the composition comprises a format selected from the group consisting of a tablet, troche, lozenge, aqueous suspension, oily suspension, emulsion, hard capsule, soft capsule, and syrup.
17. The method of claim 14 , wherein the pharmaceutical composition comprises a mixture of the compound and an erodible polymer that promotes swelling of the mixture in an aqueous environment.
18. The method of claim 17 , wherein the erodible polymer is hydroxypropyl methylcellulose (HPMC).
19. The method of claim 18 , wherein the mixture comprises the compound and HPMC in a ratio of from about 1:10 to about 10:1.
20. The method of claim 14 , wherein the pharmaceutical composition is a unit dosage comprising from about 10 mg to about 500 mg of the compound.